Legend Biotech (LEGN) Cash & Current Investments (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Cash & Current Investments data on file, last reported at $646.4 million in Q1 2026.

• Quarterly Cash & Current Investments fell 35.72% year-over-year to $646.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646.4 million (down 35.72% YoY) and the FY2025 annual result came in at $901.9 million, up 214.5% from the prior year.
• Cash & Current Investments retreated to $646.4 million in Q1 2026, from $901.9 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $1.5 billion in Q2 2023 to a low of $266.7 million in Q2 2025.
• A 5-year average of $868.1 million and a median of $901.9 million in 2025 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 77.57% — and 2025, when it jumped 214.5%.
• Tracing LEGN's Cash & Current Investments over 5 years: stood at $971.6 million in 2022, then jumped by 31.57% to $1.3 billion in 2023, then tumbled by 77.57% to $286.8 million in 2024, then jumped by 214.5% to $901.9 million in 2025, then fell by 28.33% to $646.4 million in 2026.
• The last three Cash & Current Investments figures came in at $646.4 million (Q1 2026), $901.9 million (Q4 2025), and $278.9 million (Q3 2025), per Business Quant data.